G
Generate Biomedicines
Pioneering Generative Biology to create breakthrough medicines
At a glance
- Status
- Listed
- Listing
- IPO 2026
Open roles
Generate Biomedicines in the Somerville ecosystem
The Generate Biomedicines office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later14 investors entered at this stage
- SFSamsung Life Science Fund
- MPMarch Capital Partners
- AAAbu Dhabi Investment Authority
- AFAlaska Permanent Fund
T. Rowe Price
ARCH Venture Partners- PIPictet
Morningside
Fidelity Investments- AMAmgen
- NVNVentures
Flagship Pioneering- MMMAPS Capital Management
- AVAltitude Life Science Ventures
Source: Dealroom Talent Intelligence.
Alumni founders
Former Generate Biomedicines employees who went on to found companies, sorted by Dealroom signal score.
LSLila SciencesEst. 2022
Geoffrey von MaltzahnUnited States
ABAbiologicsEst. 2020
Avak KahvejianUnited States
GBGate BioscienceEst. 2021
MHMontai HealthEst. 2022
Noubar AfeyanUnited StatesPatents
8 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See Generate Biomedicines on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
Anthropic buys Mithril Medicine, a one-person biotech that ran a muscular dystrophy drug programme with Claude
Zealand Pharma and Generate Biomedicines team up on AI-designed obesity therapies
MiRABO Biotechnology raises $2.9M pre-Series A for its antibody drug AI